Acute malaria dysregulates specialized lymph node macrophages to suppress vaccine-elicited protection against the Ebola virus

We show that a blood-stage murine <i>Plasmodium</i> infection negatively impacts the primary antibody response elicited by low-dose recombinant vesicular stomatitis virus (rVSV)/Ebola virus (EBOV) vaccination and results in reduced protection against a lethal dose of mouse-adapted EBOV. This defect occurs within the draining lymph node due to the elevation of interferon gamma elicited in <i>Plasmodium yoelii</i> (<i>Py)</i>-infected mice. The <i>Py</i>-imposed decrease in vaccine-mediated protection can be overcome with higher doses of rVSV/EBOV. While the strong protection conferred by rVSV/EBOV and significant side effects known to be associated with this vaccine have led to the suggestion that the vaccine dosage be reduced, our studies provide a rationale for maintaining the current higher dose.

Authors

Institutions

Publication Details

Journal
mBio
Published
2025-12-30
DOI
https://doi.org/10.1128/mbio.02796-25
Citations
1
Primary Topic
Viral Infections and Outbreaks Research
Type
article
Field-Weighted Citation Impact
1.40
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Acute malaria dysregulates specialized lymph node macrophages to suppress vaccine-elicited protection against the Ebola virus

Troy D. Randall, Noah S. Butler, Wendy Maury, Jobaida Akther et al.
1 citations
mBio
Viral Infections and Outbreaks Research
1.40
article

Acute malaria dysregulates specialized lymph node macrophages to suppress vaccine-elicited protection against the Ebola virus

Troy D. Randall, Noah S. Butler, Wendy Maury, Jobaida Akther, Alejandro A. Pezzulo, Jonah Elliff, Andrea Marzi, Kai J. Rogers, Andrew L. Thurman, Caitlin O. Messingham, Lindsey Grady, Kyle L. O'Donnell, Rahul Vijay
article en
1 citations

Abstract

We show that a blood-stage murine <i>Plasmodium</i> infection negatively impacts the primary antibody response elicited by low-dose recombinant vesicular stomatitis virus (rVSV)/Ebola virus (EBOV) vaccination and results in reduced protection against a lethal dose of mouse-adapted EBOV. This defect occurs within the draining lymph node due to the elevation of interferon gamma elicited in <i>Plasmodium yoelii</i> (<i>Py)</i>-infected mice. The <i>Py</i>-imposed decrease in vaccine-mediated protection can be overcome with higher doses of rVSV/EBOV. While the strong protection conferred by rVSV/EBOV and significant side effects known to be associated with this vaccine have led to the suggestion that the vaccine dosage be reduced, our studies provide a rationale for maintaining the current higher dose.

mBioVol. 17(2)
University of Iowa (US), National Institutes of Health (US), Rosalind Franklin University of Medicine and Science (US), University of Alabama at Birmingham (US), National Institute of Allergy and Infectious Diseases (US), Franklin University (US)
Good health and well-being
Openalex Percentile: Top 13%
Viral Infections and Outbreaks Research
1.40
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.